Rezolute (RZLT) said Wednesday that the Independent Data Monitoring Committee has recommended continuing the biotechnology company's late-stage study to treat patients with congenital hyperinsulinism without increasing the sample size.

The study is designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism who have poorly controlled hypoglycemia, the company said.

Rezolute said enrollment for the study is on track to be completed in May, with topline data due in December.

Shares of Rezolute were up 23% in recent premarket activity.